Foresite Capital

Foresite Capital investment thesis

"Foresite Capital has been a visionary partner." Serge Saxonov, CEO & Co-Founder 10x Genomics (See Disclosures) “Foresite Capital’s deep industry knowledge and in-house expertise has helped fuel our mission to outsmart cancer resistance.” Tim Clackson Theseus Pharmaceuticals (See Disclosures) "The Foresite team contributed meaningful scientific and strategic insights that supported our path from concept to acquisition in just over two years. Their partnership allowed our small team to move more quickly and decisively than we could have alone." Chris LeMasters XinThera (See Disclosures) "The Foresite Capital team has been great collaborators as we work to push the bounds of what is possible when disparate healthcare data can be combined and accessed in a privacy-compliant manner." Andrew Kr

Foresite Capital team (19)

Partners and principals at Foresite Capital:

• Deepak Atri — sweet spot $38.5M
• Luke Bagaason — sweet spot $38.5M
• Vikram Bajaj — sweet spot $38.5M
• Jacob Barlow — sweet spot $38.5M
• Shannon Bergstedt — sweet spot $38.5M
• Hyung Chun — sweet spot $38.5M
• Marguerite Davis — sweet spot $38.5M
• Shoman Kasbekar — sweet spot $38.5M
• Richard Lau — sweet spot $38.5M
• Dorothy Margolskee — sweet spot $38.5M
• Stephen Peterson — sweet spot $38.5M
• Hemaka Rajapakse — sweet spot $38.5M
• Jonathan Robbins — sweet spot $38.5M
• Michael Rome — sweet spot $38.5M
• Dennis Ryan — sweet spot $38.5M
• Jim Tananbaum — sweet spot $38.5M
• Tony Wiemelt — sweet spot $38.5M
• Cindy Xiong — sweet spot $38.5M
• Collin Yang-Wong — sweet spot $38.5M

Foresite Capital portfolio companies

Companies listed on Foresite Capital's public materials include: Strategy, Portfolio, People, Careers, News, Blog, Filter By: All, All, Alumni, Biopharmaceutical, Healthcare Tech & Services, Life Sciences, Therapeutics, 10x Genomics (Alumni), 89 Bio, Inc. (Alumni), Abdera Therapeutics, Acceleron Pharma (Alumni), Aclaris Therapeutics, Inc. (Alumni), Adaptimmune Therapeutics PLC (Alumni), Adaptive Biotechnologies Corporation (Alumni), Adicet Bio, Inc. (Alumni), Aduro Biotech (Alumni), Aerie Pharmaceuticals, Inc. (Alumni), Aetion (Alumni), Affinivax (Alumni), Aimmune Therapeutics, Inc. (Alumni), Akero Therapeutics (Alumni), Alector (Alumni), Allogene (Alumni), Alumis, Inc. (Alumni), ALX Oncology (Alumni), Ambit Biosciences Corporation (Alumni), Arbutus Biopharma Corporation (Alumni), Arcus Biosciences, Inc. (Alumni), Ardelyx, Inc. (Alumni), Ascendis Pharma (Alumni), Audentes Therapeutics (Alumni), Avanir Pharmaceuticals, Inc. (Alumni), Avenzo Therapeutics (Alumni), Avexis (Alumni), Beam Therapeutics Inc. (Alumni), Bellicum Pharmaceuticals (Alumni), Bicara Therapeutics (Alumni), BioDelivery Sciences International, Inc. (Alumni), Biohaven Pharmaceutical (Alumni), Bit Bio Limited, Blueprint Medicines (Alumni), Candid Therapeutics (Alumni), Casi Pharmaceuticals (Alumni), Celldex Therapeutics, Inc., Centessa Pharmaceuticals, Cerevance, CG Oncology, Chimagen Biosciences, Color Health, Compass Therapeutics (Alumni), ConnectiveRx, Corvus Pharmaceuticals, Crinetics Pharmaceuticals, Inc., Crossover Health, Inc. (Alumni).

Is Foresite Capital a fit for your round?

Upload your pitch deck and see whether anyone at Foresite Capital appears in your top matches.